Abstract
BackgroundDrug survival rate is generally accepted as a reliable indicator of both efficacy and safety profile of a biological DMARD.ObjectivesTo evaluate survival rates of certolizumab-pegol (CZP) in ankylosing spondylitis (AS)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
